Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings

by Paul Quintaro, Benzinga Editor
November 26, 2012 10:23 AM | 16 seconds read |
Navidea Biopharmaceuticals, Inc. NAVB today announced that data from its Lymphoseek^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!